Net Income

China's top pig producer wins a major ESG award by turning waste into wealth, cutting carbon equivalent to 600M trees, and boosting farmer incomes.

Ditching the old OEM model for a 'win-win ecosystem,' Chery bets on shared tech and green manufacturing. A global summit will test this bold new vision.

The market for at-home NAD+ therapy is booming, but as telehealth offers new convenience, it faces a wave of regulatory and safety questions.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

Allogene Therapeutics faces a make-or-break moment as it prepares to unveil crucial trial data for its 'off-the-shelf' cancer therapy, cema-cel.

Stephan Crétier, who turned a $25k loan into a $14B security empire, will keynote at SWGSB, offering bankers crucial lessons in risk and resilience.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

Gensler's Andy Cohen joins the REIT's board, signaling a strategic shift toward design-led development in LA and Honolulu's premium real estate markets.

After sweeping awards, 'The Ebony Canal' takes its powerful message on Black maternal health from Hollywood to a global stage, aiming for systemic change.

With revenue soaring 265%, Primior Holdings' bet on its GAIA blockchain platform is paying off, bridging real estate with the future of digital assets.

In a major strategic coup, Barnes & Thornburg acquires an elite 12-lawyer insurance group, creating a national powerhouse and shaking up the legal market.

A hidden danger in IV lines causes thousands of preventable deaths. Now, one company is showcasing a new strategy to protect patients from this 'gross gap'.

The diagnostics firm posts strong 2025 growth, but the impending loss of a key partner puts its high-stakes strategic pivot squarely to the test.

IM Cannabis has 180 days to raise its stock price above $1.00 or risk delisting from Nasdaq, highlighting broader struggles in the global cannabis sector.

The deal with Sample Healthcare signals a major shift from managing data to using AI to execute revenue cycle tasks, tackling costs and staffing shortages.

Lead Real Estate’s ENT TERRACE hotels secure prestigious Booking.com awards, reflecting a successful strategy in Japan's booming extended-stay market.

As pet owners seek unique items, advanced laser engravers are empowering a new wave of entrepreneurs to tap into a multi-billion dollar market.

Amaero's major titanium powder agreement signals a massive production boost, aiming to strengthen the US supply chain for defense and aerospace industries.

The passing of Gordon Bowerman, Yangarra's chairman for over two decades, leaves a legacy of growth and a critical question of succession for the company.